XERSXeris Biopharma Holdings, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 72). Price is +46% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Level with the previous count, down from 7.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How XERS is trading
Xeris Biopharma Holdings, Inc. is +36% over the past year while the S&P 500 is +18%: 17 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +46%
vs 200-day average · a clear uptrend
- RSI (14)
- 72
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 0.00%
Below its 52-week high
Details›
- Last close2026-10-09
- $10.48
- 1 monthS&P 500 +2.7%
- +37%
- 1 yearS&P 500 +18%
- +36%
- 5 yearsS&P 500 +88%
- +300%
- vs 50-day average$8.64
- +21%
- 52-week high
- $10.47
- 52-week low
- $5.29
- Annualised volatility
- 56%
| Year | Return |
|---|---|
| 2026 (year to date) | +33% |
| 2025 | +132% |
| 2024 | +44% |
| 2023 | +77% |
| 2022 | −55% |
| 2021 | −40% |
| 2020 | −30% |
| 2019 | −59% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 3 of 8 | −7.0% |
| Feb | 8 | 5 of 8 | −3.1% |
| Mar | 8 | 4 of 8 | −3.3% |
| Apr | 8 | 4 of 8 | +3.4% |
| May | 8 | 6 of 8 | +15% |
| Jun | 8 | 4 of 8 | −3.4% |
| Jul | 9 | 5 of 9 | +0.40% |
| Aug | 9 | 6 of 9 | +19% |
| Sep | 9 | 4 of 9 | −4.2% |
| Oct | 9 | 5 of 9 | +0.71% |
| Nov | 8 | 4 of 8 | −2.5% |
| Dec | 8 | 5 of 8 | +5.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore